Vetter and Rentschler Biopharma have announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. The desired goal of the collaboration is to create long-term value through the alignment of manufacturing approaches that enable clients to bring their products to patients more easily and faster.
“We are pleased to collaborate with such a highly respected and successful company. Like us, Vetter is a family-run and well-established service provider. We have known each other for many years and share a commitment to high quality standards and sustainable value creation. Our strategic collaboration is aimed at reducing complexity for our clients, with the joint overarching goal of bringing promising new therapies to patients with serious and rare diseases faster than before,” said Prof. Dr. Nikolaus F. Rentschler, Chairman of the Board of Rentschler Biopharma.
“It is important for businesses to sometimes think outside the box. Pursuing future-oriented and innovative ideas is part of both of our companies’ DNA. The alignment of Rentschler Biopharma’s experience in drug substance manufacturing and our own core competency in drug product pharmaceutical manufacturing is yet another opportunity to pursue,” Senator h.c. Udo J. Vetter, Chairman of the Advisory Board of Vetter, said.
The alliance of the two CDMOs will leverage Rentschler Biopharma’s experience in drug substance manufacturing, including bioprocess development and API production, and Vetter’s knowledge in aseptic fill and finish and secondary packaging. The companies have already identified opportunities, where early and active exchange information and best-practice will benefit both clients and their drug products.
Both companies will continue to independently address and service current and new clients as they explore opportunities for cooperative integration of approaches to complex molecules.